KR102497728B1 - 림프종 치료를 위한 ｅｚｈ2 억제제 - Google Patents

림프종 치료를 위한 ｅｚｈ2 억제제 Download PDF

Info

Publication number
KR102497728B1
KR102497728B1 KR1020177000760A KR20177000760A KR102497728B1 KR 102497728 B1 KR102497728 B1 KR 102497728B1 KR 1020177000760 A KR1020177000760 A KR 1020177000760A KR 20177000760 A KR20177000760 A KR 20177000760A KR 102497728 B1 KR102497728 B1 KR 102497728B1
Authority
KR
South Korea
Prior art keywords
lymphoma
ezh2
subject
nhl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177000760A
Other languages
English (en)
Korean (ko)
Other versions
KR20170052558A (ko
Inventor
헤이케 케일해크
론 오티슨
라리사 레이더맨
사라 케이. 넛슨
엘. 다니엘 존스턴
Original Assignee
에피자임, 인코포레이티드
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에피자임, 인코포레이티드, 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에피자임, 인코포레이티드
Priority to KR1020237004113A priority Critical patent/KR20230031963A/ko
Publication of KR20170052558A publication Critical patent/KR20170052558A/ko
Application granted granted Critical
Publication of KR102497728B1 publication Critical patent/KR102497728B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177000760A 2014-06-17 2015-06-17 림프종 치료를 위한 ｅｚｈ2 억제제 Active KR102497728B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237004113A KR20230031963A (ko) 2014-06-17 2015-06-17 림프종 치료를 위한 ｅｚｈ2 억제제

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462013522P 2014-06-17 2014-06-17
US62/013,522 2014-06-17
US201462036265P 2014-08-12 2014-08-12
US62/036,265 2014-08-12
PCT/US2015/036310 WO2015195848A1 (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004113A Division KR20230031963A (ko) 2014-06-17 2015-06-17 림프종 치료를 위한 ｅｚｈ2 억제제

Publications (2)

Publication Number Publication Date
KR20170052558A KR20170052558A (ko) 2017-05-12
KR102497728B1 true KR102497728B1 (ko) 2023-02-09

Family

ID=54936086

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177000760A Active KR102497728B1 (ko) 2014-06-17 2015-06-17 림프종 치료를 위한 ｅｚｈ2 억제제
KR1020237004113A Ceased KR20230031963A (ko) 2014-06-17 2015-06-17 림프종 치료를 위한 ｅｚｈ2 억제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237004113A Ceased KR20230031963A (ko) 2014-06-17 2015-06-17 림프종 치료를 위한 ｅｚｈ2 억제제

Country Status (21)

Country Link
US (5) US10166238B2 (enExample)
EP (2) EP3157527B1 (enExample)
JP (1) JP6779793B2 (enExample)
KR (2) KR102497728B1 (enExample)
CN (2) CN113289022A (enExample)
AU (3) AU2015277139A1 (enExample)
BR (1) BR112016029492A2 (enExample)
CA (1) CA2952074C (enExample)
DK (1) DK3157527T3 (enExample)
EA (1) EA038337B1 (enExample)
ES (1) ES2948442T3 (enExample)
FI (1) FI3157527T3 (enExample)
HU (1) HUE062158T2 (enExample)
IL (3) IL285201B2 (enExample)
LT (1) LT3157527T (enExample)
MX (2) MX383866B (enExample)
PL (1) PL3157527T3 (enExample)
PT (1) PT3157527T (enExample)
SG (2) SG10201811128RA (enExample)
SI (1) SI3157527T1 (enExample)
WO (1) WO2015195848A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
RU2018145311A (ru) 2012-10-15 2019-02-18 Эпизайм, Инк. Способы лечения рака
AU2014360078A1 (en) 2013-12-06 2016-06-09 Epizyme, Inc. Combination therapy for treating cancer
PT3157527T (pt) 2014-06-17 2023-06-30 Eisai R&D Man Co Ltd Inibidores de ezh2 para tratamento de linfoma
SG10201903356XA (en) * 2014-10-16 2019-05-30 Epizyme Inc Method for treating cancer
SG11201703806XA (en) * 2014-11-17 2017-06-29 Epizyme Inc Method for treating cancer
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
EA201792304A1 (ru) 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
AU2017211331A1 (en) * 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
WO2018136596A1 (en) * 2017-01-20 2018-07-26 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019014191A1 (en) * 2017-07-10 2019-01-17 Constellation Pharmaceuticals, Inc. GENE EXPRESSION INDUCED BY EZH2 INHIBITOR
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
CN114555112A (zh) * 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
JP2023527116A (ja) * 2020-05-28 2023-06-27 エピザイム インコーポレイテッド がんを治療するためのｅｚｈ２阻害剤の使用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JP2014534178A (ja) 2011-09-30 2014-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 癌の処置方法
AU2013232229B2 (en) * 2012-03-12 2017-11-23 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
SG10201608579UA (en) 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
LT2836491T (lt) 2012-04-13 2017-03-27 Epizyme, Inc. Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6461802B2 (ja) 2012-10-15 2019-01-30 エピザイム，インコーポレイティド 置換ベンゼン化合物
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
NZ708563A (en) * 2012-11-01 2019-02-22 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014100080A1 (en) 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
AU2014254392B2 (en) 2013-03-15 2018-05-24 Epizyme, Inc. Substituted benzene compounds
AU2014273946B2 (en) * 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
US10260102B2 (en) 2013-10-09 2019-04-16 Roche Molecular Systems, Inc. Methods and compositions for detecting mutation in the human EZH2 gene
HUE063984T2 (hu) 2013-10-16 2024-02-28 Epizyme Inc Hidroklorid só forma az EZH2 gátlásához
EP3057594A4 (en) 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
AU2014360078A1 (en) 2013-12-06 2016-06-09 Epizyme, Inc. Combination therapy for treating cancer
PT3157527T (pt) 2014-06-17 2023-06-30 Eisai R&D Man Co Ltd Inibidores de ezh2 para tratamento de linfoma
US20190000860A1 (en) 2014-11-06 2019-01-03 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
SG11201703806XA (en) 2014-11-17 2017-06-29 Epizyme Inc Method for treating cancer
JP6544507B2 (ja) 2015-02-09 2019-07-17 日本精機株式会社 ヘッドアップディスプレイ装置
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
KR20170095656A (ko) 2016-02-15 2017-08-23 동부대우전자 주식회사 방열구조를 갖는 세탁기

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular cancer therapeutics, 2014, 13(4), 842-854*

Also Published As

Publication number Publication date
PT3157527T (pt) 2023-06-30
EP3157527A1 (en) 2017-04-26
CN106999498A (zh) 2017-08-01
IL285201B1 (en) 2024-01-01
AU2020244382B2 (en) 2022-08-04
EA201692285A8 (ru) 2018-01-31
CA2952074A1 (en) 2015-12-23
WO2015195848A8 (en) 2016-07-07
CN106999498B (zh) 2021-06-08
ES2948442T3 (es) 2023-09-12
KR20170052558A (ko) 2017-05-12
EP3157527B1 (en) 2023-05-24
MX2016016744A (es) 2017-11-30
EP3157527A4 (en) 2018-05-23
HUE062158T2 (hu) 2023-10-28
US20190175604A1 (en) 2019-06-13
AU2015277139A1 (en) 2016-12-22
PL3157527T3 (pl) 2023-08-07
EP4252851A3 (en) 2023-11-22
WO2015195848A1 (en) 2015-12-23
JP2017518334A (ja) 2017-07-06
DK3157527T3 (da) 2023-07-03
SG10201811128RA (en) 2019-01-30
LT3157527T (lt) 2023-07-25
US10166238B2 (en) 2019-01-01
AU2020244382A1 (en) 2020-10-29
EA038337B1 (ru) 2021-08-11
US20240058348A1 (en) 2024-02-22
NZ727108A (en) 2023-09-29
IL309539A (en) 2024-02-01
IL285201A (en) 2021-08-31
IL285201B2 (en) 2024-05-01
MX2021007651A (es) 2021-08-11
AU2022263523A1 (en) 2022-12-08
BR112016029492A2 (pt) 2017-10-17
IL249438A0 (en) 2017-02-28
US20170216300A1 (en) 2017-08-03
US20200022987A1 (en) 2020-01-23
EA201692285A1 (ru) 2017-06-30
CN113289022A (zh) 2021-08-24
US20200323866A1 (en) 2020-10-15
US11642347B2 (en) 2023-05-09
EP4252851A2 (en) 2023-10-04
KR20230031963A (ko) 2023-03-07
JP6779793B2 (ja) 2020-11-04
SI3157527T1 (sl) 2023-09-29
MX383866B (es) 2025-03-14
FI3157527T3 (fi) 2023-07-25
SG11201610273VA (en) 2017-01-27
CA2952074C (en) 2022-08-30

Similar Documents

Publication Publication Date Title
KR102497728B1 (ko) 림프종 치료를 위한 ｅｚｈ2 억제제
AU2022256115A1 (en) Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type
JP7121660B2 (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
US20230181549A1 (en) Use of ezh2 inhibitors for treating cancer
US20190038633A1 (en) Methods of treating cancer
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
HK40097684A (en) Ezh2 inhibitors for treating lymphoma
NZ727108B2 (en) Ezh2 inhibitors for treating lymphoma
HK40074912B (zh) 用ezh2抑制剂治疗mrto/sccoht的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000